Depressive Disorders

116 soru

Soru 21Soru →

A 2828-year-old software engineer presents to the clinic with a 44-week history of profound sadness, poor concentration, and a 55-kg (1111-lb) weight gain. She reports sleeping up to 1414 hours a day and feeling a "heavy sensation" in her arms and legs. She has stopped attending social events and is struggling to meet her project deadlines. Her medical history is unremarkable, and she takes no medications. When asked about past psychiatric symptoms, she recalls a 66-day period during college when she felt "unstoppable," slept only 22 to 33 hours a night without feeling tired, and wrote an entire novel. During that time, friends noted she was speaking much faster than usual, though her behavior did not result in hospitalization or academic failure. Vital signs are within normal limits. Laboratory results show a thyroid-stimulating hormone level of 1.8μU/mL1.8 \mu U/mL (normal: 0.50.5 to 5.0μU/mL5.0 \mu U/mL) and a negative urine toxicology screen. Which of the following is the most appropriate next step in pharmacotherapy for this patient?

Cevabı ve açıklamayı göster

Cevap: Initiate lurasidone therapy

Cevap

Initiate lurasidone therapy
The patient is presenting with a major depressive episode characterized by atypical features (hypersomnia, hyperphagia, leaden paralysis). Crucially, her history of a distinct 66-day period of abnormally elevated mood, decreased need for sleep, and increased goal-directed activity (writing a novel) without severe impairment or hospitalization meets the criteria for a hypomanic episode. Therefore, her correct diagnosis is bipolar II disorder, currently in a depressive episode. First-line pharmacotherapy for bipolar depression includes mood stabilizers or specific second-generation antipsychotics such as lurasidone, quetiapine, or cariprazine. Lurasidone is an appropriate and effective choice that targets her depressive symptoms without risking mood destabilization.

Adım Adım Çözüm

1
Identify the current syndrome from the clinical presentation.
The patient exhibits depressed mood, weight gain, hypersomnia, and leaden paralysis for 44 weeks.
These symptoms fulfill the criteria for a major depressive episode with atypical features.
2
Evaluate the patient's psychiatric history for prior mood episodes.
The patient reports a distinct 66-day period of elevated mood, decreased need for sleep, and increased goal-directed activity.
Because this episode lasted at least 44 days and did not cause severe functional impairment or require hospitalization, it meets the criteria for a hypomanic episode.
3
Synthesize the diagnosis.
Major depressive episode plus a history of a hypomanic episode confirms the diagnosis of Bipolar II disorder.
Differentiating unipolar major depressive disorder from bipolar depression is a critical diagnostic step before initiating pharmacotherapy.
4
Determine the appropriate evidence-based pharmacotherapy.
Select a medication approved for bipolar depression, such as lurasidone.
Standard antidepressants (SSRIs) must be avoided as monotherapy in bipolar disorder to prevent mood destabilization.

Anahtar Kavram

Patients presenting with a depressive episode must be screened for a history of mania or hypomania to accurately differentiate between major depressive disorder and bipolar disorder, which dictates the choice of pharmacotherapy.
Soru 22Soru →

A 34-year-old graphic designer comes to the office for a follow-up visit. Four weeks ago, she presented with pervasive sadness, hypersomnia, increased appetite, and a heavy feeling in her limbs. She was diagnosed with a major depressive episode and started on sertraline 50 mg daily. Today, she reports that her mood has not improved and she is frustrated. She says, "I stopped taking the pill three days ago because it wasn't working fast enough. Can we just try something else?" Upon further questioning, the patient mentions that three years ago, she experienced a 10-day period where she felt "incredibly energized," required only 2 hours of sleep per night without feeling tired, and impulsively drained her savings account to start a speculative business venture that quickly failed. She has no history of hallucinations or delusions. Physical examination is unremarkable. Which of the following is the most appropriate next step in management?

Cevabı ve açıklamayı göster

Cevap: Initiate therapy with an atypical antipsychotic such as quetiapine

Cevap

Initiate therapy with an atypical antipsychotic such as quetiapine.
The correct answer recognizes that this patient has Bipolar I Disorder, currently in a depressive episode. Her history of a 10-day period of extreme energy, decreased need for sleep, and severe impulsivity meets the diagnostic criteria for a manic episode. In the treatment of bipolar depression, antidepressant monotherapy (such as resuming sertraline or switching to bupropion) is generally contraindicated because it can precipitate a manic switch and is frequently ineffective. First-line treatments for acute bipolar depression include specific atypical antipsychotics (e.g., quetiapine, lurasidone, cariprazine) or mood stabilizers (e.g., lithium, lamotrigine). Therefore, initiating quetiapine is the most appropriate next step in her management.

Adım Adım Çözüm

1
Analyze the patient's past psychiatric history.
The patient describes a 10-day period of severe elevated energy, decreased need for sleep, and impulsive financial behavior.
These symptoms meet the DSM-5 criteria for a manic episode (lasting at least 7 days), which changes the primary diagnosis from Major Depressive Disorder (MDD) to Bipolar I Disorder.
2
Evaluate the current presentation in the context of the new diagnosis.
The patient is currently experiencing a bipolar depressive episode with atypical features (hypersomnia, hyperphagia, leaden paralysis).
Treatment guidelines for bipolar depression differ significantly from unipolar depression.
3
Identify the contraindications in the current or proposed pharmacological plan.
Resuming sertraline or switching to another antidepressant monotherapy (like bupropion) is contraindicated due to the risk of precipitating a manic switch. Adding an MAOI is contraindicated due to the lack of a 14-day washout period.
Bipolar depression requires mood stabilizers or specific atypical antipsychotics, and combining serotonergic drugs inappropriately risks Serotonin Syndrome.
4
Select the most appropriate evidence-based therapy.
Initiating quetiapine is correct.
Quetiapine (along with lurasidone, lithium, and lamotrigine) is an established first-line treatment for acute bipolar depression.

Anahtar Kavram

Patients presenting with depressive episodes must be carefully screened for a lifetime history of mania or hypomania. If a history of mania is present, the diagnosis is Bipolar I Disorder, and antidepressant monotherapy is generally contraindicated due to the risk of inducing a manic switch.
Soru 23Soru →

A 45-year-old man is diagnosed with a first episode of severe, non-psychotic major depressive disorder. He is medically healthy and has no previous psychiatric treatment history. According to standard stepped-care guidelines for major depressive disorder, arrange the following therapeutic management steps in the most appropriate chronological sequence, assuming the patient exhibits only a partial response to each consecutive intervention.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence for managing treatment-resistant depression is to first initiate first-line monotherapy, optimize its dosage, augment with a second agent upon partial response, and finally consider neuromodulation such as ECT if pharmacological options are exhausted.
The stepped-care approach to major depressive disorder prioritizes efficacy while minimizing side effects and polypharmacy. It begins with a single well-tolerated agent. If the response is partial, the clinician's first obligation is to ensure the dose is optimized to confirm whether it is a true failure at therapeutic levels. If partial response persists despite dose optimization, augmentation (e.g., with a second-generation antipsychotic) is indicated to boost efficacy. Finally, if the patient fails multiple adequate medication trials, they are deemed to have treatment-resistant depression, at which point interventional treatments like ECT become appropriate.

Adım Adım Çözüm

1
Establish the diagnosis and select initial therapy.
Initiate first-line pharmacotherapy with a selective serotonin reuptake inhibitor (SSRI).
SSRIs are standard first-line agents with a favorable efficacy and side-effect profile for non-psychotic major depressive disorder.
2
Assess clinical response at 4 to 8 weeks.
Optimize the dosage of the initial SSRI to the maximum tolerated level.
A common cause of perceived treatment failure is an inadequate dose; maximizing the dose ensures an adequate trial before discarding the medication.
3
Re-evaluate after dose optimization reveals only partial improvement.
Augment the current regimen with a second-generation antipsychotic or lithium.
For partial responders to an adequate monotherapy trial, adding an augmenting agent targets residual symptoms without discarding the partial benefit of the SSRI.
4
Assess for treatment-resistant depression after multiple failed pharmacological trials.
Refer the patient for electroconvulsive therapy (ECT) or repetitive transcranial magnetic stimulation (rTMS).
When standard step-care psychopharmacology fails, the patient meets criteria for treatment-resistant depression, indicating the need for highly effective neuromodulation.

Anahtar Kavram

Stepped-care management of Major Depressive Disorder involves initial monotherapy, dose optimization, augmentation or switching strategies, and ultimately neuromodulation for treatment-resistant cases.
Soru 24Soru →

A 29-year-old woman presents to the primary care clinic reporting a 6-week history of depressed mood, profound fatigue, and an inability to concentrate at work. She notes that her appetite has significantly increased, leading to a 4-kg (8.8-lb) weight gain. She often sleeps for 12 hours a night but still wakes up feeling unrefreshed, and states that her arms and legs frequently feel "like lead." Her medical history is unremarkable, and she takes no medications. Her vital signs are within normal limits. She recalls experiencing a similar episode of depression during her first year of college, which eventually resolved without treatment. The physician is considering initiating pharmacotherapy for her symptoms. Which of the following is the most appropriate next step in management?

Cevabı ve açıklamayı göster

Cevap: Elicit a detailed history regarding periods of impulsivity, grandiosity, and decreased need for sleep

Cevap

Elicit a detailed history regarding periods of impulsivity, grandiosity, and decreased need for sleep
This patient presents with a major depressive episode characterized by atypical features (leaden paralysis, hypersomnia, weight gain, and profound fatigue). Before prescribing any antidepressant therapy, it is a critical requirement to screen every patient for a lifetime history of manic or hypomanic episodes. Bipolar disorder frequently begins with depressive episodes, and atypical features are particularly common in bipolar depression. If an antidepressant is given as monotherapy to a patient with unrecognized bipolar disorder, it can precipitate a manic or hypomanic episode (antidepressant-induced manic switch). Therefore, eliciting a history of impulsivity, grandiosity, and a decreased need for sleep is the most appropriate and necessary next step.

Adım Adım Çözüm

1
Identify the primary clinical syndrome
The patient is experiencing a major depressive episode with atypical features, indicated by mood reactivity, hypersomnia, hyperphagia, and leaden paralysis.
Recognizing the current episode characteristics is necessary to determine the appropriate diagnostic and management pathways.
2
Evaluate the risk of bipolar disorder
The patient has a history of a prior depressive episode at a young age and current atypical features, both of which are commonly associated with bipolar depression.
Bipolar disorder often presents initially with depressive episodes, and recognizing this underlying vulnerability alters treatment significantly.
3
Determine the necessary prerequisite before initiating pharmacotherapy
The physician must screen for a lifetime history of mania or hypomania.
Starting an antidepressant (such as an SSRI) without a mood stabilizer in a patient with bipolar disorder can precipitate a dangerous manic switch.

Anahtar Kavram

All patients presenting with a major depressive episode must be screened for a history of manic or hypomanic episodes before initiating antidepressant monotherapy to avoid precipitating a manic switch.
Soru 25Soru →

A 45-year-old man with no prior psychiatric history is diagnosed with Major Depressive Disorder. Over the next two years, his condition proves difficult to manage, requiring escalating interventions based on his varying levels of therapeutic response at each stage. According to evidence-based guidelines for stepped-care psychiatric management, arrange the following clinical interventions in the most appropriate chronological order, progressing from initial presentation to the management of severe treatment-resistant depression.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct chronological sequence for managing progressive treatment-resistant depression is: 1) Initial SSRI monotherapy optimization, 2) Switching to a different agent (SNRI) due to complete non-response, 3) Augmenting with an atypical antipsychotic due to partial response, and 4) Proceeding to Electroconvulsive Therapy (ECT) after multiple failed pharmacological trials.
The correct algorithm for depression pharmacotherapy relies on assessing the degree of response at each interval. Initial therapy utilizes an SSRI. If no response is observed after an adequate trial (4-6 weeks at max dose), a switch to a different monotherapy is indicated. If that subsequent trial yields a partial response, guidelines recommend augmenting with agents like aripiprazole, lithium, or thyroid hormone rather than switching again. Finally, if the depression remains functionally debilitating despite these sequential optimized medication trials (true treatment resistance), neuromodulation techniques such as ECT become the definitive standard of care.

Adım Adım Çözüm

1
Identify the standard first-line treatment for an initial depressive episode.
Initial SSRI monotherapy and dose optimization is the starting point.
SSRIs have a favorable side effect profile and are the standard of care for initiating MDD treatment.
2
Determine the appropriate action for a complete non-response after an adequate 6-week trial.
Switching to a different monotherapy (e.g., an SNRI) is the next step.
Without any clinical improvement, augmenting is generally less effective than switching entirely to a medication with a potentially different mechanism or receptor binding profile.
3
Determine the appropriate action for a partial clinical response to the second trial.
Augmentation with a second agent (e.g., atypical antipsychotic) is indicated.
When a patient exhibits partial improvement, augmenting allows the clinician to preserve existing therapeutic gains while targeting residual symptoms.
4
Identify the definitive treatment for severe depression that has failed multiple pharmacological steps.
Referral for Electroconvulsive Therapy (ECT).
ECT is the most effective treatment for profound, treatment-resistant depression (failure of 2+ adequate trials of distinct classes/combinations).

Anahtar Kavram

Stepped-care management of Major Depressive Disorder (Switching vs. Augmentation vs. Neuromodulation)
Tahmini Süre:1m 30s
Soru 26Soru →

A 26-year-old male graduate student presents to the university health center complaining of severe sadness, lack of motivation, and poor concentration over the past 5 weeks. He states he has completely lost interest in his coursework and hobbies, which is highly unusual for him. He struggles to get out of bed, sleeping up to 14 hours a day, and reports a 5 kg (11 lb) weight gain during this time. Medical history is unremarkable, and he takes no medications. Physical examination reveals psychomotor retardation and a blunted affect, but vital signs and the remainder of the examination are within normal limits. He denies any suicidal ideation. The patient requests an antidepressant medication to help him "get back on track." Which of the following is the most appropriate next step in the clinical evaluation or management of this patient?

Cevabı ve açıklamayı göster

Cevap: Elicit a history of lifetime manic or hypomanic episodes.

Cevap

The most appropriate next step is to screen the patient for a lifetime history of manic or hypomanic episodes.
This patient presents with a major depressive episode featuring atypical symptoms (hypersomnia, weight gain). Atypical features are particularly common in bipolar depression. The most critical next step before starting any antidepressant is to screen for a lifetime history of manic or hypomanic episodes. Treating unrecognized bipolar depression with antidepressant monotherapy carries a significant risk of precipitating a manic switch. If the patient has a history of mania/hypomania, mood stabilizers or atypical antipsychotics would be indicated instead of standard antidepressant monotherapy.

Adım Adım Çözüm

1
Identify the primary clinical presentation.
The patient is experiencing a major depressive episode characterized by atypical features, specifically hypersomnia and weight gain.
Recognizing the symptom cluster helps guide the differential diagnosis, as atypical features are frequently seen in the depressive phase of bipolar disorder.
2
Determine the necessary safety and diagnostic evaluations prior to initiating pharmacotherapy.
The physician must screen for a history of mania or hypomania.
Antidepressant monotherapy can precipitate a manic or hypomanic episode (manic switch) in patients with underlying bipolar disorder. All patients presenting with major depression must be screened for bipolarity before prescribing unopposed antidepressants.

Anahtar Kavram

Prior to starting antidepressant monotherapy for a major depressive episode, clinicians must screen for a history of manic or hypomanic episodes to prevent precipitating a manic switch in patients with undiagnosed bipolar disorder.
Soru 27Soru →

Match each patient's clinical presentation with the most appropriate next step in psychopharmacologic or procedural management.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

A 72-year-old man with major depressive disorder refuses to eat or drink for 4 days, resulting in acute kidney injury. He is actively hallucinating that his internal organs are rotting.
A 58-year-old man presents with depressed mood, anhedonia, and insomnia 4 weeks after an acute anterior wall myocardial infarction. He is clinically stable on his current cardiac medications.
A 24-year-old man with newly diagnosed major depressive disorder reports severe insomnia and weight loss. He has a history of epilepsy on levetiracetam and requests a treatment lacking sexual side effects.
A 45-year-old woman on escitalopram 20 mg daily for 8 weeks reports only partial improvement in her depressive symptoms. She continues to struggle with profound daytime fatigue and poor concentration.
A 62-year-old woman with breast cancer presents with major depression. She recently started tamoxifen therapy. She requests medication to improve her mood and manage severe concurrent hot flashes.

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

The 72-year-old man with food refusal requires electroconvulsive therapy. The 58-year-old man post-myocardial infarction requires sertraline. The 24-year-old man with epilepsy requires mirtazapine. The 45-year-old woman with residual fatigue requires bupropion augmentation. The 62-year-old woman on tamoxifen requires venlafaxine.
Each patient requires a highly specific intervention based on their medical comorbidities and symptom profiles. Electroconvulsive therapy is required for life-threatening psychotic depression. Sertraline is chosen for post-myocardial infarction safety. Mirtazapine is selected to avoid sexual dysfunction in a patient who cannot take bupropion due to epilepsy. Bupropion is added to an SSRI for partial response with residual fatigue. Venlafaxine is chosen to avoid CYP2D6 interactions with tamoxifen while also effectively treating concurrent hot flashes.

Adım Adım Çözüm

1
Analyze the 72-year-old man's presentation.
Severe major depressive disorder with psychotic features and life-threatening oral refusal.
Identify the need for an emergent, rapid-acting intervention (electroconvulsive therapy) over slower-acting pharmacotherapy.
2
Evaluate the 58-year-old man's medical history.
Recent myocardial infarction requires a cardiac-safe antidepressant.
Sertraline is the best-studied and safest SSRI for patients with recent ischemic cardiac events.
3
Assess the 24-year-old man's specific requests and absolute contraindications.
Needs an agent without sexual side effects but cannot take bupropion due to epilepsy.
Mirtazapine avoids sexual dysfunction, does not significantly lower the seizure threshold, and addresses his concurrent severe insomnia.
4
Review the 45-year-old woman's treatment progress.
Partial response to an SSRI with persistent residual fatigue and poor concentration.
Bupropion augmentation is the standard next step to target these specific residual symptoms without discontinuing the partially effective SSRI.
5
Determine safe oncologic and psychiatric options for the 62-year-old woman on tamoxifen.
Must avoid CYP2D6 inhibitors to maintain tamoxifen efficacy, while also treating vasomotor symptoms.
Venlafaxine lacks significant CYP2D6 inhibition and is a first-line non-hormonal treatment for severe hot flashes.

Anahtar Kavram

Management of major depressive disorder must be strictly tailored to the patient's specific symptom profile, medical comorbidities, concurrent medications, and the acuity of the clinical situation.
Tahmini Süre:3m 0s
Soru 28Soru →

A 35-year-old man is diagnosed with major depressive disorder in the outpatient clinic. Over the next year, he experiences persistent symptoms despite good medication adherence, requiring a progressive escalation of his treatment plan. Arrange the following management steps in the standard chronological order for escalating treatment of major depressive disorder, proceeding from initial pharmacological therapy to the management of highly refractory disease.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence of treatment escalation is: 1) Initiate SSRI monotherapy, 2) Optimize the SSRI dosage, 3) Augment with a different medication class, 4) Initiate electroconvulsive therapy.
The standard pharmacological management of major depressive disorder follows a stepped-care approach to balance efficacy with side effects. Treatment begins with first-line monotherapy, usually an SSRI. If the initial response is inadequate after an appropriate duration (typically 4 to 6 weeks), the dose is optimized to the maximum tolerated amount. If the patient remains non-responsive, the next step involves switching to another agent or augmenting with a different class of medication (such as bupropion or an atypical antipsychotic) to target multiple neurotransmitter pathways. Finally, for patients who prove to be highly treatment-resistant after multiple adequate pharmacological trials, neuromodulation therapies like electroconvulsive therapy (ECT) are indicated.

Adım Adım Çözüm

1
Identify the first-line treatment for major depressive disorder.
Initiate monotherapy with an SSRI.
SSRIs have a favorable side effect profile and are the standard initial pharmacological choice for MDD.
2
Determine the next step for a patient with inadequate response to the initial SSRI dose.
Optimize the dosage of the initial SSRI.
Before abandoning a medication trial, the dose should be maximized to ensure the lack of response is not simply due to under-dosing.
3
Determine the step for a patient who fails an optimized dose of monotherapy.
Augment with a medication from a different class.
Augmentation (e.g., with bupropion, mirtazapine, or second-generation antipsychotics) leverages different neurotransmitter systems to achieve a therapeutic response.
4
Identify the treatment of choice for severe, refractory depression.
Initiate electroconvulsive therapy (ECT).
ECT is typically positioned at the end of the treatment algorithm for outpatients who have exhausted multiple medication trials without success.

Anahtar Kavram

Stepped-care treatment algorithm for major depressive disorder
Soru 29Soru →

A 24-year-old woman is brought to the clinic by her husband due to severe sadness and social withdrawal for the past 6 weeks. She has been sleeping 12 to 14 hours a day, has poor appetite, and struggles to concentrate on daily tasks. She frequently complains of feeling cold. Laboratory studies show a thyroid-stimulating hormone (TSH) level of 1.5 µU/mL and a normal free T4 level. Her husband notes that two years ago, she had a 3-week period where she barely slept, spoke so rapidly it was hard to interrupt her, and recklessly spent thousands of dollars on unneeded home renovations. The patient is currently not taking any medications. Which of the following is the most appropriate next step in management?

Cevabı ve açıklamayı göster

Cevap: Initiate quetiapine

Cevap

Initiate quetiapine
The patient is currently experiencing a major depressive episode. However, her history of a 3-week period characterized by decreased need for sleep, rapid speech, and impulsive spending meets the criteria for a manic episode. This confirms a diagnosis of bipolar I disorder, currently in a depressed phase. The most appropriate treatment for bipolar depression includes atypical antipsychotics such as quetiapine or lurasidone, or mood stabilizers such as lithium. Quetiapine is a first-line agent for this presentation.

Adım Adım Çözüm

1
Analyze the patient's current symptoms.
The patient has severe sadness, hypersomnia, poor appetite, and poor concentration lasting 6 weeks.
To establish the presence of a major depressive episode.
2
Identify key historical information.
The patient had a distinct 3-week episode of decreased need for sleep, rapid speech, and impulsive spending two years ago.
To differentiate between unipolar major depressive disorder and bipolar disorder.
3
Formulate a diagnosis.
The combination of a current major depressive episode and a past manic episode indicates a diagnosis of bipolar I disorder, currently in a depressed phase.
To guide appropriate pharmacotherapy selection.
4
Select the appropriate treatment.
Quetiapine is selected as it is an FDA-approved first-line treatment for bipolar depression.
Antidepressant monotherapy (like SSRIs or SNRIs) must be avoided to prevent a manic switch.

Anahtar Kavram

Bipolar I Disorder, Depressed Phase
Tahmini Süre:1m 0s
Soru 30Soru →

A 24-year-old woman is brought to the emergency department by her husband due to worsening depressive symptoms over the past 3 weeks. She reports feeling profoundly sad, sleeping up to 14 hours a day, and experiencing significant psychomotor retardation. For the past 2 weeks, she has been hearing a persistent voice telling her that she is "worthless and should die," and she admits to having a specific plan to overdose on her medications. Her husband reports that 3 years ago, she had a distinct 1-week period where she barely slept, exhibited grandiose behavior, and engaged in impulsive spending that resulted in severe financial debt. Three days ago, her primary care provider diagnosed her with major depressive disorder and started her on fluoxetine. Laboratory studies reveal a thyroid-stimulating hormone (TSH) level of 0.2 mU/L0.2 \text{ mU/L} (normal: 0.5−5.0 mU/L0.5-5.0 \text{ mU/L}) and a free T4 of 0.6 ng/dL0.6 \text{ ng/dL} (normal: 0.9−1.7 ng/dL0.9-1.7 \text{ ng/dL}). Which of the following is the most appropriate next step in management?

Cevabı ve açıklamayı göster

Cevap: Admit to the inpatient psychiatric unit and initiate quetiapine

Cevap

The most appropriate next step is to admit the patient to the inpatient psychiatric unit and initiate quetiapine.
The correct answer addresses two critical factors: patient safety and appropriate psychopharmacology. The patient's active suicidal plan necessitates immediate inpatient psychiatric hospitalization. Diagnostically, her history of a 1-week manic episode establishes Bipolar I Disorder. Her current presentation is a severe bipolar depressive episode with psychotic features (auditory hallucinations). Quetiapine is a first-line treatment for bipolar depression and its antipsychotic properties will concurrently treat her hallucinations. The fluoxetine prescribed by her primary care provider is inappropriate monotherapy for bipolar disorder and should be discontinued.

Adım Adım Çözüm

1
Analyze the patient's psychiatric history to establish the primary diagnosis.
The history of a 1-week episode of decreased sleep, grandiosity, and impulsive spending confirms a past manic episode, establishing a diagnosis of Bipolar I Disorder.
A single manic episode is sufficient to diagnose Bipolar I Disorder, fundamentally altering the treatment algorithm for any subsequent depressive episodes.
2
Evaluate the current clinical presentation.
The patient has a 3-week history of severe depression with 2 weeks of mood-congruent auditory hallucinations and a specific suicidal plan.
This presentation indicates a current major depressive episode with psychotic features, which represents a psychiatric emergency.
3
Determine the appropriate setting for care.
Inpatient psychiatric admission is required.
The patient has active suicidal ideation with a specific plan and access to lethal means (medications), making outpatient management unsafe.
4
Select the appropriate pharmacotherapy.
Initiate an atypical antipsychotic approved for bipolar depression, such as quetiapine.
Quetiapine provides established monotherapy efficacy for bipolar depression while simultaneously treating the concurrent psychotic features. Fluoxetine (an SSRI) must be discontinued as it is inappropriate monotherapy for bipolar disorder.

Anahtar Kavram

Management of severe Bipolar I depression with psychotic features requires inpatient admission for safety and treatment with medications effective for both mood and psychosis (e.g., quetiapine), while avoiding antidepressant monotherapy.
Tahmini Süre:2m 0s
Soru 31Soru →

A 32-year-old woman comes to the outpatient clinic 4 months postpartum for a follow-up evaluation of depressive symptoms. Two weeks ago, she presented with a 4-week history of profound despondency, early morning awakenings, anorexia with a 3-kg (6.6-lb) weight loss, and feeling worse in the morning. She reported that these symptoms made it exceedingly difficult to get out of bed and properly care for her infant. At that time, she was diagnosed with major depressive disorder and started on escitalopram 10 mg daily. Today, she states, "The medication isn't working. I still feel incredibly depressed, but now I also feel extremely restless, jittery, and my thoughts are racing." Vital signs are within normal limits. On examination, the patient appears visibly agitated, is pacing the room, and exhibits rapid speech. Upon detailed psychiatric review, she mentions that during her second year of college, she experienced a spontaneous 6-day period where she felt "incredibly energized," slept only 3 hours per night without fatigue, and impulsively maxed out two credit cards on unnecessary clothing. That episode resolved without medical intervention. Which of the following is the most appropriate next step in pharmacotherapy?

Cevabı ve açıklamayı göster

Cevap: Discontinue escitalopram and initiate quetiapine

Cevap

Discontinue escitalopram and initiate quetiapine
This patient initially presented with a major depressive episode and was appropriately treated for unipolar depression based on the initial assessment. However, her current presentation of profound depression mixed with severe agitation, pacing, and racing thoughts shortly after starting an SSRI is highly suspicious for a treatment-emergent mixed state. A detailed history reveals a prior spontaneous 6-day episode of decreased need for sleep, increased energy, and impulsivity, which meets the DSM-5 criteria for a hypomanic episode. Therefore, her correct diagnosis is Bipolar II disorder. Antidepressant monotherapy (like escitalopram) is contraindicated in bipolar disorder due to the risk of mood destabilization. The most appropriate next step is to discontinue the offending SSRI and initiate a medication that is FDA-approved for acute bipolar depression, such as the atypical antipsychotic quetiapine.

Adım Adım Çözüm

1
Evaluate the patient's past psychiatric history from the clinical interview.
The patient describes a distinct 6-day period of elevated mood, decreased need for sleep, and impulsive behavior in college.
Identifying past episodes of abnormally elevated mood is crucial to differentiate unipolar major depressive disorder from bipolar disorder. A 4-to-6 day period of these symptoms without marked impairment or hospitalization defines a hypomanic episode, establishing a diagnosis of Bipolar II disorder.
2
Assess the patient's current response to the prescribed SSRI.
After 2 weeks of escitalopram, the patient has worsening depression alongside new-onset severe agitation, restlessness, pacing, and racing thoughts.
When a patient with an underlying bipolar spectrum disorder is treated with antidepressant monotherapy, it can precipitate mood destabilization, leading to a mixed state (depressive symptoms combined with psychomotor agitation and racing thoughts) or a full manic switch.
3
Determine the appropriate pharmacologic intervention.
The SSRI must be stopped, and a medication indicated for acute bipolar depression should be started.
Continuing the SSRI will exacerbate the mixed state. Quetiapine, lurasidone, or a combination of olanzapine and fluoxetine are first-line, FDA-approved treatments for acute bipolar depression that provide efficacy without the high risk of mood destabilization.

Anahtar Kavram

Patients presenting with depressive episodes must be carefully screened for a history of mania or hypomania. Antidepressant monotherapy in patients with unrecognized Bipolar II disorder can induce severe agitation, mixed states, or manic switches, necessitating immediate cessation of the antidepressant and initiation of a bipolar-specific agent.
Soru 32Soru →

A 54-year-old male architect is evaluated for a first episode of pervasive sadness, early morning awakening, and severe anhedonia. Over the subsequent 14 months, his clinical course is characterized by progressive treatment resistance, ultimately culminating in an inpatient psychiatric admission for life-threatening symptoms. According to evidence-based stepped-care guidelines for Major Depressive Disorder, arrange the following management steps in the most appropriate chronological order, corresponding to his clinical evolution from initial presentation to severe, refractory illness.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct chronological sequence of stepped-care management is: 1) Screen for bipolar disorder and medical mimics, 2) Initiate SSRI monotherapy, 3) Switch to an SNRI due to non-response and side effects, 4) Augment with aripiprazole for partial response, and 5) Initiate ECT for the development of psychotic features and food refusal.
The management of Major Depressive Disorder follows a highly evidence-based stepped-care algorithm. First, all patients must be screened for bipolar disorder and medical mimics (e.g., hypothyroidism) before initiating treatment to avoid precipitating mania. Second, an SSRI is the appropriate first-line pharmacotherapy. Third, if a patient has a complete lack of response and experiences intolerable side effects, the correct algorithmic step is to switch to a different class of antidepressant (e.g., an SNRI). Fourth, if a subsequent trial yields a partial response and is well-tolerated, the algorithm shifts to augmentation (e.g., adding an atypical antipsychotic like aripiprazole or a mood stabilizer like lithium) to build upon the partial gains. Finally, if the patient clinically deteriorates and develops life-threatening features, such as psychosis, catatonia, or refusal to eat, all standard outpatient pharmacotherapy algorithms are superseded by the need for immediate Electroconvulsive Therapy (ECT).

Adım Adım Çözüm

1
Establish diagnosis and safety parameters.
Screen for bipolar disorder and check TSH.
Rule out bipolar disorder and medical mimics to prevent antidepressant-induced mania before any pharmacotherapy is started.
2
Initiate primary pharmacotherapy.
Start SSRI monotherapy.
SSRIs are the first-line standard of care for an uncomplicated initial episode of unipolar major depressive disorder.
3
Manage primary treatment failure.
Switch to an SNRI.
A complete lack of response combined with poor tolerability dictates switching to a different antidepressant class rather than augmenting.
4
Manage partial therapeutic response.
Augment with aripiprazole.
Partial improvement with good tolerability dictates adding an augmenting agent (like a second-generation antipsychotic or lithium) rather than abandoning the current effective drug.
5
Manage life-threatening clinical deterioration.
Initiate Electroconvulsive Therapy (ECT).
The emergence of psychotic features and food refusal represents a psychiatric emergency requiring immediate, highly effective intervention, for which ECT is the gold standard.

Anahtar Kavram

Stepped-care pharmacotherapy algorithm for Major Depressive Disorder (MDD), specifically distinguishing indications for switching versus augmentation, and identifying absolute indications for ECT.
Soru 33Soru →

A 31-year-old male accountant presents to the clinic for an urgent follow-up appointment. He initially presented two weeks ago with a one-month history of severe sadness, hypersomnia, and profound anhedonia. At that time, he was diagnosed with a major depressive episode and prescribed fluoxetine. Today, he reports that his mood has not improved, but he now feels "extremely irritable, wired, and completely unable to sit still." His physical examination is notable for rapid, pressured speech and psychomotor agitation. Upon detailed psychiatric review, the patient admits that he experienced a similar "wired" state twice in his twenties. During those episodes, which each lasted approximately ten days, he required only two hours of sleep per night and impulsively spent thousands of dollars on unneeded electronics. He has no significant past medical history and denies any illicit substance use. Which of the following is the most appropriate next step in management?

Cevabı ve açıklamayı göster

Cevap: Discontinue the fluoxetine and initiate treatment with a mood stabilizer such as quetiapine

Cevap

The most appropriate next step is to discontinue the selective serotonin reuptake inhibitor (fluoxetine) and initiate treatment with a mood stabilizer or atypical antipsychotic (such as quetiapine).
The patient's history of episodes involving decreased sleep, impulsivity, and a "wired" state lasting approximately 10 days confirms a diagnosis of Bipolar I Disorder. His initial presentation of a depressive episode was misdiagnosed as unipolar major depressive disorder. Initiating fluoxetine (an SSRI) as monotherapy in a patient with bipolar disorder has precipitated a manic switch, characterized by his current pressured speech, irritability, and psychomotor agitation. The most critical next step is to immediately discontinue the offending antidepressant and initiate an appropriate treatment for bipolar depression, such as the atypical antipsychotic quetiapine.

Adım Adım Çözüm

1
Identify the patient's initial diagnosis and current presentation.
The patient was initially diagnosed with major depressive disorder and given an SSRI. He now presents with agitation, irritability, and pressured speech.
Tracking the timeline of symptoms relative to medication initiation is critical for identifying adverse drug effects.
2
Analyze the newly obtained psychiatric history.
The patient has a history of distinct episodes lasting at least 7 days characterized by decreased need for sleep, impulsivity, and euphoric/wired mood.
These historical symptoms meet the DSM-5 criteria for past manic episodes, changing the baseline diagnosis from unipolar depression to Bipolar I Disorder.
3
Determine the etiology of the current acute symptoms.
The current agitation and pressured speech represent a manic switch or severe activation syndrome triggered by antidepressant monotherapy in a patient with bipolar disorder.
Selective serotonin reuptake inhibitors can precipitate manic episodes in patients with underlying bipolar disorder.
4
Select the appropriate pharmacological intervention.
The offending agent (fluoxetine) must be discontinued, and an appropriate medication for bipolar depression (e.g., quetiapine, lurasidone, or lithium) must be started.
Antidepressant monotherapy is contraindicated in Bipolar I Disorder. Mood stabilizers or specific atypical antipsychotics are the standard of care.

Anahtar Kavram

Patients presenting with depressive symptoms must be screened for a history of mania or hypomania prior to initiating antidepressant monotherapy to prevent precipitating a manic switch.
Soru 34Soru →

A 62-year-old man comes to the cardiology clinic for a routine follow-up 6 weeks after being hospitalized for an acute anterior wall myocardial infarction, for which he received a drug-eluting stent. His cardiac function has stabilized, and he is compliant with his medication regimen, which includes aspirin, clopidogrel, metoprolol, lisinopril, and atorvastatin. Today, his wife expresses deep concern about his emotional well-being since discharge. The patient states, 'My life is basically over. I am just a burden to my family now, and there is no point in going on.' He reports a 10-lb (4.5-kg) weight loss due to poor appetite and says he wakes up every day at 3:00 AM unable to fall back asleep. He admits to recurrent thoughts that his family would be better off if he were dead, though he lacks a specific suicide plan. His physical examination is unremarkable, and an electrocardiogram shows normal sinus rhythm with a QTc interval of 420 ms. Which of the following is the most appropriate next step in the pharmacologic management of this patient?

Cevabı ve açıklamayı göster

Cevap: Initiate sertraline

Cevap

Initiate sertraline
The correct answer is to initiate sertraline. This patient is presenting with a severe episode of major depressive disorder (MDD) following a myocardial infarction (MI), a condition that independently increases cardiovascular mortality risk. Selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment. Among the SSRIs, sertraline and escitalopram are considered the safest and most efficacious choices for patients with ischemic heart disease, as established by the SADHART trial. Furthermore, sertraline has minimal inhibitory effects on cytochrome P450 enzymes. This is crucial because the patient is taking clopidogrel, a prodrug that requires activation by the hepatic enzyme CYP2C19. Sertraline will not interfere with this activation, ensuring the patient's dual antiplatelet therapy remains effective.

Adım Adım Çözüm

1
Diagnose the patient's psychiatric condition based on the clinical presentation.
The patient meets criteria for Major Depressive Disorder (MDD) with melancholic features (depressed mood, guilt, significant weight loss, early morning awakening, and passive suicidal ideation lasting longer than 2 weeks).
Establishing the correct psychiatric diagnosis is required to determine the indication for pharmacotherapy.
2
Evaluate the patient's medical history and current medication regimen for potential contraindications.
The patient is 62 years old, 6 weeks post-myocardial infarction with a recent stent, and is taking dual antiplatelet therapy (aspirin and clopidogrel).
Medical comorbidities and concurrent medications dictate the safety profile required for the chosen psychotropic agent.
3
Select the most appropriate antidepressant that lacks adverse cardiovascular effects and avoids dangerous drug-drug interactions.
Sertraline is selected because it has a proven cardiovascular safety profile in post-MI patients and minimally inhibits CYP450 enzymes.
Other agents carry risks of QT prolongation (high-dose citalopram), arrhythmias (TCAs), hypertension (SNRIs), or dangerous CYP2C19 inhibition preventing clopidogrel activation (fluoxetine).

Anahtar Kavram

Pharmacologic management of major depressive disorder in patients with recent myocardial infarction and concurrent cardiovascular medications.
Tahmini Süre:1m 30s
Soru 35Soru →

A 34-year-old woman comes to the clinic reporting a 6-week history of pervasive sadness, frequent tearfulness, and profound fatigue. She states that her arms and legs feel "like they are made of lead" and she is sleeping up to 14 hours a day. She feels immense guilt about being an inadequate mother to her 4-month-old infant, whom she is exclusively breastfeeding. Three years ago, the patient was prescribed paroxetine for generalized anxiety. Two weeks after starting the medication, she became unusually energetic, slept only 2 hours a night without feeling tired, and began making impulsive, large investments in cryptocurrency, which depleted her savings. The paroxetine was immediately discontinued, but her hyperactive and grandiose state persisted for another 5 weeks before gradually resolving. She has not taken any psychiatric medications since that time. Vital signs and physical examination are unremarkable. Which of the following is the most appropriate pharmacotherapy for this patient's current symptoms?

Cevabı ve açıklamayı göster

Cevap: Initiate quetiapine therapy

Cevap

Initiate quetiapine therapy
The patient's current presentation of a major depressive episode with atypical features must be viewed in the context of her psychiatric history. She previously experienced a full manic episode while on paroxetine. Crucially, the mania persisted for 5 weeks after paroxetine cessation. According to DSM-5 criteria, a manic episode that emerges during antidepressant treatment but persists at a fully syndromal level beyond the physiological effect of that drug constitutes a true manic episode, establishing a diagnosis of Bipolar I Disorder. Consequently, her current state is acute bipolar depression. Antidepressant monotherapy is contraindicated. Second-generation antipsychotics like quetiapine are first-line for bipolar depression. Furthermore, because she is exclusively breastfeeding, quetiapine is an ideal choice due to its very low excretion into breast milk, whereas other agents like lithium carry high risks of infant toxicity.

Adım Adım Çözüm

1
Analyze the current clinical presentation.
The patient is experiencing a major depressive episode with atypical features (hypersomnia, leaden paralysis) occurring 4 months postpartum.
Establishing the current syndrome is the first step in guiding psychiatric management.
2
Evaluate the past psychiatric history for exclusionary criteria.
Three years ago, she had a full manic episode (decreased sleep, grandiosity, impulsivity) triggered by paroxetine.
A history of mania completely changes the management of a depressive episode by shifting the diagnosis from Major Depressive Disorder to a Bipolar Disorder.
3
Apply DSM-5 duration rules for medication-induced symptoms.
Because the manic symptoms persisted for 5 weeks after the short-acting paroxetine was discontinued, they extended beyond the physiological effect of the drug.
A manic episode persisting beyond the physiological effect of an antidepressant establishes a diagnosis of true Bipolar I Disorder, rather than just medication-induced mania.
4
Determine the appropriate class of medication for the current episode.
The patient requires treatment for acute bipolar depression. Antidepressant monotherapy must be avoided to prevent a manic switch.
Treating bipolar depression requires mood stabilizers or specific atypical antipsychotics, not standard SSRIs/SNRIs alone.
5
Filter suitable medications based on the patient's lactation status.
Lithium poses toxicity risks to the infant. Quetiapine is efficacious for bipolar depression and safe during breastfeeding.
The patient is exclusively breastfeeding, mandating a medication with low breast milk transfer and known neonatal safety.

Anahtar Kavram

Differentiation of Bipolar I Disorder from unipolar depression based on historical antidepressant-induced mania, and selection of safe bipolar pharmacotherapy during lactation.
Tahmini Süre:2m 0s
Soru 36Soru →

Review the following patient summaries describing complex depressive presentations. Match each clinical profile with the most appropriate next step in pharmacologic or somatic management.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

An 82-year-old male with 2 months of severe depressed mood who now refuses all food and liquids, stating his intestines have completely rotted away.
A 22-year-old female with anhedonia and hypersomnia whose history includes a distinct 4-day episode of racing thoughts, decreased need for sleep, and impulsive spending that did not impair functioning.
A 35-year-old female with chronic depression, prominent mood reactivity, hyperphagia, and severe rejection sensitivity who has failed sequential trials of fluoxetine, venlafaxine, and nortriptyline.
A 45-year-old male whose depressed mood and active suicidality resolved on maximum-dose sertraline, but who currently struggles with profound residual daytime fatigue, apathy, and cognitive slowing.

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

Match each clinical profile to its targeted therapy based on specific symptom clusters, psychiatric comorbidities, and urgency: the actively starving psychotic patient requires ECT; the patient with past hypomania requires quetiapine for bipolar II depression; the treatment-resistant patient with atypical features benefits from an MAOI; and the patient with residual SSRI-induced apathy requires bupropion augmentation.
Each pairing tests a specific, advanced nuance in the algorithmic treatment of depressive disorders. Patients with severe psychotic depression and refusal to eat require immediate somatic intervention (ECT) to prevent death from dehydration or starvation. Patients presenting with depression who have a history of 4 or more days of elevated mood and energy meet criteria for Bipolar II disorder; they must be treated with bipolar-specific agents (e.g., quetiapine, lurasidone) rather than traditional antidepressants to prevent mood destabilization. Treatment-resistant depression with classic atypical features (mood reactivity, hyperphagia, leaden paralysis, rejection sensitivity) shows unique responsiveness to monoamine oxidase inhibitors (MAOIs) like phenelzine, which remain a high-yield salvage therapy for this subtype. Finally, patients who achieve remission of core depressive and suicidal symptoms on an SSRI but suffer from residual fatigue, cognitive slowing, or apathy benefit from the targeted addition of bupropion, an NDRI that addresses these specific dopaminergic/noradrenergic deficits.

Adım Adım Çözüm

1
Analyze the 82-year-old male's presentation.
Diagnosis is major depressive disorder with psychotic features (somatic delusion) and life-threatening inanition.
Severe starvation in an elderly patient is a psychiatric emergency where waiting weeks for oral pharmacotherapy to take effect is fatal, necessitating immediate somatic therapy (ECT).
2
Analyze the 22-year-old female's presentation.
Diagnosis is Bipolar II disorder based on the current depressive episode and a distinct past hypomanic episode (4 days of elevated energy/impulsivity without severe impairment).
Recognizing past hypomania is critical to avoid SSRI-induced mood destabilization and dictates the use of a bipolar-approved agent like quetiapine.
3
Analyze the 35-year-old female's presentation.
Diagnosis is treatment-resistant depression with atypical features.
Patients with atypical depression (mood reactivity, hyperphagia, leaden paralysis, rejection sensitivity) who fail standard antidepressants have a uniquely high response rate to MAOIs.
4
Analyze the 45-year-old male's presentation.
Diagnosis is MDD with a partial response to SSRI therapy and specific residual target symptoms (fatigue, anergia).
Bupropion targets dopamine and norepinephrine, directly alleviating fatigue and cognitive slowing without risking serotonin syndrome when added to an SSRI.

Anahtar Kavram

Advanced tailoring of pharmacologic and somatic management for depressive disorders based on severity, subtype (psychotic, atypical), comorbidities (bipolarity), and residual symptoms.
Soru 37Soru →

Match each patient's clinical presentation with the most appropriate primary or adjunctive treatment modality.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

A 75-year-old man with severe depressed mood, psychotic features, and life-threatening refusal to eat or drink.
A 24-year-old woman presenting with severe depression who reports a past episode of decreased need for sleep, rapid speech, and grandiosity.
A 32-year-old man with a first episode of moderate major depressive disorder without psychotic features or prior psychiatric history.
A 45-year-old woman with a history of depressive episodes that consistently begin in November and resolve by April.

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

The correct matches align the psychotic/food-refusing patient with ECT, the bipolar depression patient with quetiapine, the uncomplicated MDD patient with an SSRI, and the seasonal pattern patient with bright light therapy.
Each treatment is matched to its classic indication: ECT for rapid response in psychotic or life-threatening depression; quetiapine for bipolar depression to avoid SSRI-induced mania; SSRIs for standard major depression; and light therapy for seasonal pattern.

Adım Adım Çözüm

1
Analyze the 75-year-old man's presentation.
Severe depression with psychotic features and food refusal.
Requires the most rapid and effective intervention available, which is ECT.
2
Analyze the 24-year-old woman's presentation.
Depression with a history of mania (elevated mood, decreased sleep, grandiosity).
Indicates bipolar depression, requiring a medication with mood-stabilizing properties (like quetiapine) while avoiding SSRI monotherapy.
3
Analyze the 32-year-old man's presentation.
Uncomplicated, first-episode moderate major depressive disorder.
Warrants standard first-line pharmacotherapy with an SSRI.
4
Analyze the 45-year-old woman's presentation.
Depressive episodes strictly tied to fall and winter months.
Meets criteria for seasonal pattern, making bright light therapy a primary indication.

Anahtar Kavram

Selecting appropriate first-line and specialized treatments for various depressive presentations, including recognizing bipolar depression.
Soru 38Soru →

An 18-year-old female university freshman is evaluated at the student health center. Her roommate insisted she be seen because, over the last five weeks, the patient has been skipping classes, crying uncontrollably, and sleeping excessively. The patient reports severe anhedonia, a significant increase in appetite resulting in a 5-kg (11-lb) weight gain, and a sensation of profound physical heaviness in her limbs. Review of her medical records reveals a psychiatric hospitalization eight months ago. During that admission, which lasted 14 days, she exhibited pressured speech, severe psychomotor agitation, an almost complete lack of sleep, and auditory hallucinations commanding her to lead a new global government. She was stabilized and discharged, but subsequently stopped attending follow-up appointments. Three weeks ago, she visited an urgent care clinic for her current depressive symptoms and was started on daily citalopram. She has taken the medication faithfully but reports no improvement in her mood. Vital signs and physical examination are within normal limits. She denies any illicit substance use. Which of the following is the most appropriate pharmacological recommendation at this time?

Cevabı ve açıklamayı göster

Cevap: Withdraw citalopram and initiate quetiapine

Cevap

The most appropriate next step is to withdraw citalopram and initiate a medication approved for bipolar depression, such as quetiapine.
The correct answer involves withdrawing citalopram and initiating quetiapine. The patient's current presentation is a major depressive episode with atypical features. However, her psychiatric history reveals a clear manic episode with psychotic features (14 days of pressured speech, minimal sleep, agitation, and auditory hallucinations). This presentation establishes a diagnosis of bipolar I disorder, currently in a depressed phase. Antidepressant monotherapy (such as citalopram) is contraindicated in bipolar disorder because it lacks efficacy for bipolar depression and carries a high risk of precipitating a manic switch. The SSRI should be discontinued, and a medication approved for acute bipolar depression—such as quetiapine, lurasidone, or a combination of olanzapine and fluoxetine—should be started.

Adım Adım Çözüm

1
Identify the current clinical syndrome.
The patient is experiencing a major depressive episode with atypical features (hypersomnia, hyperphagia, leaden paralysis).
Establishing the current phase of the mood disturbance guides immediate symptom management.
2
Analyze the patient's psychiatric history for prior mood episodes.
The previous 14-day episode of decreased sleep, pressured speech, and psychosis represents a manic episode with psychotic features.
A past manic episode fundamentally changes the primary diagnosis from unipolar major depressive disorder to bipolar I disorder.
3
Determine the appropriate psychopharmacological intervention based on the correct diagnosis.
Citalopram (an SSRI) must be stopped to avoid precipitating mania. A first-line agent for acute bipolar depression, such as quetiapine, should be initiated.
Antidepressant monotherapy is contraindicated in bipolar I disorder due to the high risk of a manic switch.

Anahtar Kavram

Patients presenting with depressive episodes must be screened for past manic/hypomanic episodes to differentiate major depressive disorder from bipolar disorder. Antidepressant monotherapy is contraindicated in bipolar depression due to the risk of inducing a manic switch.
Soru 39Soru →

A concerned spouse brings her 28-year-old husband to the office for evaluation of severe lethargy and persistent low mood. For the past month, the patient has spent most days in bed, stopped attending his weekly basketball games, and experienced a 4-kg (9-lb) weight gain. During the interview, he appears visibly psychomotor retarded. Further history gathering from the spouse reveals a distinct two-week timeframe last summer when the patient slept roughly two hours nightly, exhibited pressured speech, and impulsively purchased an expensive sports car he could not afford. The patient is physically healthy and takes zero prescription or over-the-counter supplements. Which of the following is the most appropriate pharmacotherapy for this patient's current episode?

Cevabı ve açıklamayı göster

Cevap: Quetiapine

Cevap

Quetiapine
Quetiapine is a second-generation antipsychotic with mood-stabilizing properties, and it is an appropriate, FDA-approved treatment for bipolar depression. This patient's history of a distinct manic episode (decreased sleep, pressured speech, marked impulsivity) indicates a diagnosis of bipolar disorder rather than unipolar major depressive disorder. In bipolar depression, mood stabilizers or specific atypical antipsychotics are required, whereas antidepressant monotherapy is contraindicated.

Adım Adım Çözüm

1
Identify the patient's current clinical syndrome.
The patient has a 1-month history of severe low mood, anhedonia, hypersomnia, and psychomotor retardation, consistent with a major depressive episode.
Establishing the current phase of the psychiatric illness is the first step in evaluation.
2
Evaluate the patient's past psychiatric history.
The spouse describes a prior 2-week episode of decreased sleep, pressured speech, and impulsivity, consistent with a past manic episode.
Past history is critical to distinguish unipolar depression from bipolar disorder.
3
Establish the comprehensive diagnosis.
The combination of a past manic episode and a current major depressive episode solidifies the diagnosis of bipolar I disorder, currently depressed.
The correct diagnosis dictates the safety and efficacy of pharmacological options.
4
Select the appropriate pharmacotherapy.
Quetiapine is an FDA-approved medication for bipolar depression, whereas antidepressant monotherapy is avoided.
Antidepressants can precipitate a manic switch in patients with bipolar disorder.

Anahtar Kavram

Patients presenting with a major depressive episode must be screened for a history of mania or hypomania; bipolar depression should be treated with mood stabilizers or specific atypical antipsychotics (e.g., quetiapine, lurasidone) rather than antidepressant monotherapy to avoid precipitating a manic switch.
Tahmini Süre:1m 0s
Soru 40Soru →

A 35-year-old patient is diagnosed with severe Major Depressive Disorder without psychotic features. Arrange the following interventions in the standard sequential order of a stepped-care approach for this patient, progressing from the initial evaluation and management to interventions for highly treatment-resistant disease. Assume an inadequate clinical response to each preceding step.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence begins with screening for bipolar disorder and initiating first-line monotherapy, followed by optimizing or switching that monotherapy, then advancing to augmentation strategies, and finally utilizing electroconvulsive therapy for refractory cases.
The standard stepped-care algorithm for major depressive disorder begins with screening for bipolar disorder and starting a single first-line agent. If the response is inadequate, the dose is optimized or the patient is switched to another monotherapy. If monotherapy trials fail, an augmenting agent is added. Finally, if the patient is refractory to multiple pharmacological interventions, neuromodulation like ECT is utilized.

Adım Adım Çözüm

1
Identify the standard initial evaluation and treatment for Major Depressive Disorder.
Screening for bipolar disorder followed by initiation of an SSRI or other first-line monotherapy.
SSRIs are preferred initial agents due to their safety and tolerability. Bipolar screening prevents antidepressant-induced mania.
2
Determine the next step when the initial medication trial is inadequate.
Optimizing the dose or switching to another monotherapy.
Before adding multiple medications, a single agent should be optimized to its maximal effective dose, or replaced if ineffective.
3
Establish the next pharmacological step for continued treatment resistance.
Augmentation with a second-generation antipsychotic or mood stabilizer.
Once monotherapy optimization fails, combining medications with different mechanisms (augmentation) is indicated.
4
Identify the definitive treatment for severe, refractory depression.
Electroconvulsive therapy (ECT).
ECT is the most effective treatment for depression but is typically reserved for treatment resistance due to logistical requirements and cognitive side effect considerations.

Anahtar Kavram

The stepped-care pharmacological management of major depressive disorder progresses sequentially from monotherapy to augmentation, and ultimately to neuromodulation for severe treatment resistance.
ÖncekiSayfa 2 / 6Sonraki
Depressive Disorders Alıştırma Soruları — USMLE Step 2 CK — Sayfa 2 | Examkin